The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DETECTION phase II/III trial: Circulating tumor DNA–guided therapy for stage IIB/C melanoma after surgical resection.
 
Rebecca Lee
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst)
 
Dominic G. Rothwell
No Relationships to Disclose
 
Richard Jackson
No Relationships to Disclose
 
Nigel Smith
No Relationships to Disclose
 
Stephen Q Wong
No Relationships to Disclose
 
Noel Kelso
No Relationships to Disclose
 
George Burghel
No Relationships to Disclose
 
Chelsee Hewitt
No Relationships to Disclose
 
Harry Clarke
No Relationships to Disclose
 
Jackie Mitchell
No Relationships to Disclose
 
Kate Jones
No Relationships to Disclose
 
Andrew Muinonen-Martin
No Relationships to Disclose
 
Samra Turajlic
Honoraria - Clarivate; Erasmus University Medical Center EMC; MDAnderson; OpenHealth Communications
Speakers' Bureau - IDEA Pharma; Merck; MSD; Roche; Ventana Medical Systems
Research Funding - Andy Quick Charitable fund (Inst); Complete Genomics (Inst); CRUK Welcome Trust (Inst); Harry J Lloyd charitable trust (Inst); Imperial AHSC (Inst); NIHR (Inst); Rosetrees Trust (Inst); The Francis Crick Institute (Inst); The Robert Alpine Foundation (Inst); Ventana Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Clear Cell Renal Cell Carcinoma Biomarkers P113326GB; Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 and PCTGB2018/051893
Travel, Accommodations, Expenses - AACR; Ellipses Pharma; Erasmus University Medical Center EMC; ESMO; Institute of molecular medicine; Kidney Cancer Association; KTH Sweden; MD Anderson Cancer Center; Melanoma focus; Netherlands cancer institute; Pfizer; Res group; Research Degrees Team; Roche; Society for Immunotherapy of Cancer; Systems biology; Ventana Medical Systems; WK Weiser
 
Philippa Gail Corrie
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Microbiotica; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Richard Marais
Consulting or Advisory Role - Pfizer
Patents, Royalties, Other Intellectual Property - Basilea Pharmaceutical
 
Mark R. Middleton
Consulting or Advisory Role - Alkermes; Bayer; BiolineRx; Boehringer Ingelheim; Bristol-Myers Squibb; Immunocore; Kineta; Merck; Silicon Therapeutics; Vaccitech
Research Funding - Amgen (Inst); AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Immunocore (Inst); Medivir (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Salvarx (Inst); Vaccitech (Inst)
(OPTIONAL) Uncompensated Relationships - GenesisCare
 
Sarah-Jane Dawson
Consulting or Advisory Role - Adela (Inst); Inivata (Inst)
Research Funding - Cancer Therapeutics CRC (Inst)
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharpe & Dohme (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
 
Caroline Dive
Consulting or Advisory Role - AstraZeneca; Biocartis; Boehringer Ingelheim; GRAIL; Merck
Research Funding - Amgen; Angle; Astex Pharmaceuticals; AstraZeneca; Bayer; BIOVEN; BMS; Boehringer Ingelheim; Carrick Therapeutics; Celgene; Clearbridge Biomedics; Epigene Therapeutics; GlaxoSmithKline; Menarini; Merck; NeoMed; Novartis; Roche; Taiho Oncology; Thermo Fisher Scientific
 
Paul Lorigan
Honoraria - Amgen; BMS; Merck; MSD; Nektar; NeraCare GmbH; Novartis; Oncology Education; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Research Funding - BMS
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme